SOT101 is a superagonist fusion protein of interleukin (IL)-15 and the IL-15 receptor α (IL-15Rα) sushi+ domain, representing a promising clinical candidate for the treatment of cancer. SOT101 among other immune cells specifically stimulates natural killer (NK) cells and memory CD8+ T cells with no significant expansion or activation of the regulatory T cell compartment. In this study, we showed that SOT101 induced expression of cytotoxic receptors NKp30, DNAM-1 and NKG2D on human NK cells. SOT101 stimulated dose-dependent proliferation and the relative expansion of both major subsets of human NK cells, CD56brightCD16- and CD56dimCD16+, and these displayed an enhanced cytotoxicity in vitro. Using human PBMCs and isolated NK cells, we showed that SOT101 added concomitantly or used for immune cell pre-stimulation potentiated clinically approved monoclonal antibodies Cetuximab, Daratumumab and Obinutuzumab in killing of tumor cells in vitro. The anti-tumor efficacy of SOT101 in combination with Daratumumab was assessed in a solid multiple myeloma xenograft in CB17 SCID mouse model testing several combination schedules of administration in the early and late therapeutic setting of established tumors in vivo. SOT101 and Daratumumab monotherapies decreased with various efficacy tumor growth in vivo in dependence on the advancement of the tumor development. The combination of both drugs showed the strongest anti-tumor efficacy. Specifically, the sequencing of both drugs did not matter in the early therapeutic setting where a complete tumor regression was observed in all animals. In the late therapeutic treatment of established tumors Daratumumab followed by SOT101 administration or a concomitant administration of both drugs showed a significant anti-tumor efficacy over the respective monotherapies. These results suggest that SOT101 might significantly augment the anti-tumor activity of therapeutic antibodies by increasing NK cell-mediated activity in patients. These results support the evaluation of SOT101 in combination with Daratumumab in clinical studies and present a rationale for an optimal clinical dosing schedule selection.

Cytune Pharma Nantes France

Department of Immunology 2nd Faculty of Medicine and University Hospital Motol Charles University Prague Czechia

Laboratory of Tumor Immunology Institute of Microbiology of the Czech Academy of Sciences Prague Czechia

Preclinical Department SOTIO Biotech a s Prague Czechia

See more in PubMed

Robinson TO, Schluns KS. The potential and promise of IL-15 in immuno-oncogenic therapies. Immunol Lett (2017) 190:159–68. doi: 10.1016/j.imlet.2017.08.010 PubMed DOI PMC

Dutcher JP, Schwartzentruber DJ, Kaufman HL, Agarwala SS, Tarhini AA, Lowder JN, et al. . High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J Immunother Cancer (2014) 2(1):26. doi: 10.1186/s40425-014-0026-0 PubMed DOI PMC

Abbas AK, Trotta E D, Marson A, Bluestone JA. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol (2018) 3(25):1–8. doi: 10.1126/sciimmunol.aat1482 PubMed DOI

Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity (1998) 8(5):591–9. doi: 10.1016/s1074-7613(00)80564-6 PubMed DOI

Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, et al. . IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA (2000) 97(21):11445–50. doi: 10.1073/pnas.200363097 PubMed DOI PMC

Waldmann TA. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: Implications for cancer therapy. Cancer Immunol Res (2015) 3(3):219–27. doi: 10.1158/2326-6066.CIR-15-0009 PubMed DOI PMC

Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, Grotzinger J, et al. . Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins J Biol Chem (2006) 281(3):1612–9. doi: 10.1074/jbc.M508624200 PubMed DOI

Bouchaud G, Garrigue-Antar L, Sole V, Quemener A, Boublik Y, Mortier E, et al. . The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol (2008) 382(1):1–12. doi: 10.1016/j.jmb.2008.07.019 PubMed DOI

Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. . IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med (2009) 206(1):25–34. doi: 10.1084/jem.20082013 PubMed DOI PMC

Huntington ND, Alves NL, Legrand N, Lim A, Strick-Marchand H, Mention JJ, et al. . IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci USA (2011) 108(15):6217–22. doi: 10.1073/pnas.1019167108 PubMed DOI PMC

Bessard A, Sole V, Bouchaud G, Quemener A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther (2009) 8(9):2736–45. doi: 10.1158/1535-7163.MCT-09-0275 PubMed DOI

Desbois M, Le Vu P, Coutzac C, Marcheteau E, Beal C, Terme M, et al. . IL-15 trans-signaling with the superagonist RLI promotes Effector/Memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists. J Immunol (2016) 197(1):168–78. doi: 10.4049/jimmunol.1600019 PubMed DOI

Vincent M, Quemener A, Jacques Y. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. Oncoimmunology (2013) 2(11):e26441. doi: 10.4161/onci.26441 PubMed DOI PMC

Vincent M, Teppaz G, Lajoie L, Sole V, Bessard A, Maillasson M, et al. . Highly potent anti-CD20-RLI immunocytokine targeting established human b lymphoma in SCID mouse. mAbs (2014) 6(4):1026–37. doi: 10.4161/mabs.28699 PubMed DOI PMC

Huntington ND, Puthalakath H, Gunn P, Naik E, Michalak EM, Smyth MJ, et al. . Interleukin 15-mediated survival of natural killer cells is determined by interactions among bim, noxa and mcl-1. Nat Immunol (2007) 8(8):856–63. doi: 10.1038/ni1487 PubMed DOI PMC

Huntington ND. The unconventional expression of IL-15 and its role in NK cell homeostasis. Immunol Cell Biol (2014) 92(3):210–3. doi: 10.1038/icb.2014.1 PubMed DOI

Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer (2020) 19(1):120. doi: 10.1186/s12943-020-01238-x PubMed DOI PMC

Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol (2018) 18(11):671–88. doi: 10.1038/s41577-018-0061-z PubMed DOI

Moretta A. Natural killer cells and dendritic cells: Rendezvous in abused tissues. Nat Rev Immunol (2002) 2(12):957–64. doi: 10.1038/nri956 PubMed DOI

Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. . Innate or adaptive immunity? the example of natural killer cells. Science (2011) 331(6013):44–9. doi: 10.1126/science.1198687 PubMed DOI PMC

Luetke-Eversloh M, Cicek BB, Siracusa F, Thom JT, Hamann A, Frischbutter S, et al. . NK cells gain higher IFN-gamma competence during terminal differentiation. Eur J Immunol (2014) 44(7):2074–84. doi: 10.1002/eji.201344072 PubMed DOI

Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol (2014) 92(3):221–9. doi: 10.1038/icb.2013.98 PubMed DOI

Barrow AD, Martin CJ, Colonna M. The natural cytotoxicity receptors in health and disease. Front Immunol (2019) 10:909. doi: 10.3389/fimmu.2019.00909 PubMed DOI PMC

Lanier LL, Phillips JH, Hackett J, Jr., Tutt M, Kumar V. Natural killer cells: Definition of a cell type rather than a function. J Immunol (1986) 137(9):2735–9. PubMed

Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: An important NK cell subset. Immunology (2009) 126(4):458–65. doi: 10.1111/j.1365-2567.2008.03027.x PubMed DOI PMC

Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. . Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 97(10):3146–51. doi: 10.1182/blood.v97.10.3146 PubMed DOI

Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood (2010) 115(11):2167–76. doi: 10.1182/blood-2009-08-238469 PubMed DOI PMC

Dubois S, Conlon KC, Muller JR, Hsu-Albert J, Beltran N, Bryant BR, et al. . IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56(bright) NK cells and increases NK-cell cytokine release capabilities. Cancer Immunol Res (2017) 5(10):929–38. doi: 10.1158/2326-6066.CIR-17-0279 PubMed DOI PMC

Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, et al. . CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest (2017) 127(11):4042–58. doi: 10.1172/JCI90387 PubMed DOI PMC

Moretta L. Dissecting CD56dim human NK cells. Blood (2010) 116(19):3689–91. doi: 10.1182/blood-2010-09-303057 PubMed DOI

Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inoges S, et al. . Antibody-dependent cell cytotoxicity: Immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol (2017) 95(4):347–55. doi: 10.1038/icb.2017.6 PubMed DOI

Lo Nigro C, Macagno M, Sangiolo D, Bertolaccini L, Aglietta M, Merlano MC. NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: Biological evidence and clinical perspectives. Ann Trans Med (2019) 7(5):105. doi: 10.21037/atm.2019.01.42 PubMed DOI PMC

Kang TH, Jung ST. Boosting therapeutic potency of antibodies by taming fc domain functions. Exp Mol Med (2019) 51(11):1–9. doi: 10.1038/s12276-019-0345-9 PubMed DOI PMC

Moga E, Alvarez E, Canto E, Vidal S, Rodriguez-Sanchez JL, Sierra J, et al. . NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against b-cell lymphoma. Exp Hematol (2008) 36(1):69–77. doi: 10.1016/j.exphem.2007.08.012 PubMed DOI

Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, et al. . IL-15 and IL-2 increase cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res Treat (2011) 130(2):465–75. doi: 10.1007/s10549-011-1360-2 PubMed DOI

Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, et al. . The IL-15-Based ALT-803 complex enhances FcgammaRIIIa-triggered NK cell responses and In vivo clearance of b cell lymphomas. Clin Cancer res: An Off J Am Assoc Cancer Res (2016) 22(3):596–608. doi: 10.1158/1078-0432.CCR-15-1419 PubMed DOI PMC

Desbois M, Beal C, Charrier M, Besse B, Meurice G, Cagnard N, et al. . IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: Implications for antimetastatic treatment. J immunother Cancer (2020) 8(1):1–13. doi: 10.1136/jitc-2020-000632 PubMed DOI PMC

Pinette A, McMichael E, Courtney NB, Duggan M, Benner BN, Choueiry F, et al. . An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck. Cancer Immunol Immunother (2019) 68(8):1379–89. doi: 10.1007/s00262-019-02372-2 PubMed DOI PMC

Schmohl JU, Felices M, Taras E, Miller JS, Vallera DA. Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker. Mol Ther (2016) 24(7):1312–22. doi: 10.1038/mt.2016.88 PubMed DOI PMC

Dubois S, Patel HJ, Zhang M, Waldmann TA, Muller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol (2008) 180(4):2099–106. doi: 10.4049/jimmunol.180.4.2099 PubMed DOI

Guo Y, Luan L, Rabacal W, Bohannon JK, Fensterheim BA, Hernandez A, et al. . IL-15 superagonist-mediated immunotoxicity: Role of NK cells and IFN-gamma. J Immunol (2015) 195(5):2353–64. doi: 10.4049/jimmunol.1500300 PubMed DOI PMC

Felices M, Lenvik AJ, McElmurry R, Chu S, Hinderlie P, Bendzick L, et al. . Continuous treatment with IL-15 exhausts human NK cells via a metabolic defect. JCI Insight (2018) 3(3):1–14. doi: 10.1172/jci.insight.96219 PubMed DOI PMC

Elpek KG, Rubinstein MP, Bellemare-Pelletier A, Goldrath AW, Turley SJ. Mature natural killer cells with phenotypic and functional alterations accumulate upon sustained stimulation with IL-15/IL-15Ralpha complexes. Proc Natl Acad Sci USA (2010) 107(50):21647–52. doi: 10.1073/pnas.1012128107 PubMed DOI PMC

Frutoso M, Morisseau S, Tamzalit F, Quemener A, Meghnem D, Leray I, et al. . Emergence of NK cell hyporesponsiveness after two IL-15 stimulation cycles. J Immunol (2018) 201(2):493–506. doi: 10.4049/jimmunol.1800086 PubMed DOI

Hangasky JA, Waldmann TA, Santi DV. Interleukin 15 pharmacokinetics and consumption by a dynamic cytokine sink. Front Immunol (2020) 11:1813. doi: 10.3389/fimmu.2020.01813 PubMed DOI PMC

Biswas SK, Lopez-Collazo E. Endotoxin tolerance: New mechanisms, molecules and clinical significance. Trends Immunol (2009) 30(10):475–87. doi: 10.1016/j.it.2009.07.009 PubMed DOI

Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol (2002) 168(3):1356–61. doi: 10.4049/jimmunol.168.3.1356 PubMed DOI

Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, et al. . Crosstalk between human IgG isotypes and murine effector cells. J Immunol (2012) 189(7):3430–8. doi: 10.4049/jimmunol.1200356 PubMed DOI

Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, et al. . Affinity of human IgG subclasses to mouse fc gamma receptors. mAbs (2017) 9(5):767–73. doi: 10.1080/19420862.2017.1323159 PubMed DOI PMC

Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, et al. . IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci USA (2018) 115(46):E10915–E24. doi: 10.1073/pnas.1811615115 PubMed DOI PMC

Novel PD-1-targeted, activity-optimized IL-15 mutein SOT201 acting in cis provides antitumor activity superior to PD1-IL2v

Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers